• Je něco špatně v tomto záznamu ?

Anticoagulation Duration After First Venous Thromboembolism: Real-Life Data From the International, Observational WHITE Study

G. Palareti, AA. Bignamini, M. Cini, YJ. Li, T. Urbanek, J. Madaric, K. Bouslama, GY. Sokurenko, GM. Andreozzi, J. Matuška, A. Mansilha, V. Barinov

. 2021 ; 27 (-) : 10760296211049402. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012545

BACKGROUND: International guidelines recommend at least three months anticoagulation in all patients after acute venous thromboembolism (VTE) and suggest those with unprovoked events be considered for indefinite anticoagulation if the risk of recurrence is high and the risk of bleeding during treatment non-high. Other authors have recently argued against using a dichotomy unprovoked/provoked events to decide on anticoagulation duration and suggest instead using overall risk factors present in each patient as the basis for deciding. AIM: This sub-analysis of the WHITE study aimed at assessing the reasons for the treatment decisions taken by doctors in different countries. RESULTS: 1240 patients were recruited in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, and Tunisia). Anticoagulation was extended in 51.7% and 49.3% of patients with unprovoked or provoked events (n.s.); stopped in 15.4% versus 28.9% (P < .0001), and changed to antithrombotic drugs (sulodexide or aspirin) in 32.9% versus 21.8% (P < .0001). In the 430 subjects with isolated distal deep vein thrombosis (IDDVT) anticoagulation was stopped in 34.4%, continued in 37.0% (mainly those with post-thrombotic syndrome [PTS]) and switched to antithrombotics in the balance. High risk of recurrence was the most prevalent reason (>83% of cases) given to continue anticoagulation, regardless of nature and site of the index events, followed by risk of bleeding and presence of PTS signs. CONCLUSION: On average, attending physicians estimated the risk of recurrence in real life conditions, and the consequent therapeutic decision, using all the information available, not limiting to the location or nature of the index event.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012545
003      
CZ-PrNML
005      
20220506125833.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/10760296211049402 $2 doi
035    __
$a (PubMed)34841907
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Palareti, Gualtiero $u Arianna Anticoagulazione Foundation, Bologna, Italy $1 https://orcid.org/0000000243279561
245    10
$a Anticoagulation Duration After First Venous Thromboembolism: Real-Life Data From the International, Observational WHITE Study / $c G. Palareti, AA. Bignamini, M. Cini, YJ. Li, T. Urbanek, J. Madaric, K. Bouslama, GY. Sokurenko, GM. Andreozzi, J. Matuška, A. Mansilha, V. Barinov
520    9_
$a BACKGROUND: International guidelines recommend at least three months anticoagulation in all patients after acute venous thromboembolism (VTE) and suggest those with unprovoked events be considered for indefinite anticoagulation if the risk of recurrence is high and the risk of bleeding during treatment non-high. Other authors have recently argued against using a dichotomy unprovoked/provoked events to decide on anticoagulation duration and suggest instead using overall risk factors present in each patient as the basis for deciding. AIM: This sub-analysis of the WHITE study aimed at assessing the reasons for the treatment decisions taken by doctors in different countries. RESULTS: 1240 patients were recruited in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, and Tunisia). Anticoagulation was extended in 51.7% and 49.3% of patients with unprovoked or provoked events (n.s.); stopped in 15.4% versus 28.9% (P < .0001), and changed to antithrombotic drugs (sulodexide or aspirin) in 32.9% versus 21.8% (P < .0001). In the 430 subjects with isolated distal deep vein thrombosis (IDDVT) anticoagulation was stopped in 34.4%, continued in 37.0% (mainly those with post-thrombotic syndrome [PTS]) and switched to antithrombotics in the balance. High risk of recurrence was the most prevalent reason (>83% of cases) given to continue anticoagulation, regardless of nature and site of the index events, followed by risk of bleeding and presence of PTS signs. CONCLUSION: On average, attending physicians estimated the risk of recurrence in real life conditions, and the consequent therapeutic decision, using all the information available, not limiting to the location or nature of the index event.
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
650    _2
$a hemokoagulace $x fyziologie $7 D001777
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a rizikové faktory $7 D012307
650    _2
$a žilní tromboembolie $x epidemiologie $x etiologie $x prevence a kontrola $7 D054556
651    _2
$a Čína $x epidemiologie $7 D002681
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Bignamini, Angelo A $u School of Specialization in Hospital Pharmacy, 9304University of Milan, Milan, Italy
700    1_
$a Cini, Michela $u Arianna Anticoagulazione Foundation, Bologna, Italy $1 https://orcid.org/0000000196816159
700    1_
$a Li, Young-Jun $u Peking Union Medical College, 12501Chinese Academy of Medical Sciences, Beijing, China
700    1_
$a Urbanek, Tomasz $u 49613Medical University of Silesia, Katowice, Poland
700    1_
$a Madaric, Juraj $u Clinic of Angiology, Comenius University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia
700    1_
$a Bouslama, Kamel $u Faculty of Medicine of Tunis, 59074University of Tunis El Manar, Tunis, Tunisia
700    1_
$a Sokurenko, German Y $u North-West Mechnikov State Medical University, St. Petersburg, Russia
700    1_
$a Andreozzi, Giuseppe M $u Angiology Unit, 9308University of Padua, Padova, Italy
700    1_
$a Matuška, Jiří $u Clinical Trial Centre, Hodonin, Czechia
700    1_
$a Mansilha, Armando $u 26706University of Porto, Porto, Portugal
700    1_
$a Barinov, Victor $u Clinical Hospital N. 1 "Volynskaya", Moscow, Russia
773    0_
$w MED00001108 $t Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis $x 1938-2723 $g Roč. 27, č. - (2021), s. 10760296211049402
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34841907 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506125826 $b ABA008
999    __
$a ok $b bmc $g 1789944 $s 1163746
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 27 $c - $d 10760296211049402 $e - $i 1938-2723 $m Clinical and applied thrombosis/hemostasis $n Clin Appl Thromb Hemost $x MED00001108
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace